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Abstract
Background: The DNA mismatch repair (MMR) pathway is an important post-replicative repair
process. It is involved in the maintenance of genomic stability and MMR genes have therefore been
named the proofreaders of replicating DNA. These genes repair the replicative errors of DNA and
are thus imperative for genomic stability.
The MMR genes have been found to be involved in promoting cytotoxicity, apoptosis, p53
phosphorylation and cell cycle arrest following exposure to exogenous DNA damaging agents. Loss
of MMR function prevents the correction of replicative errors leading to instability of the genome,
and can be detected by polymorphisms in micro satellites (1–6 nucleotide repeat sequences
scattered in whole of the genome). This phenomenon, known as micro satellite instability (MSI), is
a hallmark of MMR dysfunction and can be used as a marker of MMR dysfunction in colorectal and
other malignancies. An alternative method for detection of MMR dysfunction is to test the
expression of protein products of the MMR genes by immunohistochemistry (IHC), as mutations
in these genes lead to reduced or absent expression of their gene products.
Correlation between loss of MMR function and clinical, histopathological, behavioral parameters of
the tumor and its response to chemotherapy in breast cancers may be of value in predicting tumor
behavior and response to neoadjuvant chemotherapy (NACT). Neoadjuvant chemotherapy is an
integral part of multimodal therapy for locally advanced breast cancer and predicting response may
help in tailoring regimens in patients for optimum response.
Materials : After approval by the IRB(Institutional Review Board) and ethical committee of the
hospital, 31 cases of locally advanced breast carcinoma (LABC) were studied to assess the
correlation between MMR dysfunction, clinicopathological parameters and objective clinical
response to neoadjuvant chemotherapy using immunohistochemistry. The immunohistochemical
analysis for four MMR protein products -MLH1, MSH2, MSH6 and PMS2 was done in the pre
NACT trucut biopsy specimen and after three cycles of NACT with C AF (cyclophosphamide,
adriamycin, 5-fluorouracil) regimen, in the modified radical mastectomy specimen.
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Results and conclusion: There was no significant correlation observed between expression of
MMR proteins and age, family history, tumor size or histological type. However there was a
statistically significant negative correlation between MLH1, MSH2 expression and histological
grade. There was also a negative correlation observed between PMS2 expression after neo-
adjuvant chemotherapy and clinical response. Cases with high post NACT expression of PMS2
were poor responders to chemotherapy. MSH6 was the most frequently altered MMR gene, with
a negativity rate of 48% and the patients with high expression responded poorly to NACT. The
study highlights the possible role of MMR expression in predicting aggressive tumor behavior
(histological grade) and response to neoadjuvant chemotherapy in patients with LABC.
Background
Breast cancer is second only to cancer of the cervix in
India[1,2].The standard of care in India for locally
advanced breast cancer is neoadjuvant chemother-
apy(NACT) followed by surgery in the form of modified
radical mastectomy and subsequently three more cycles of
adjuvant chemotherapy. NACT facilitates local as well as
distant control of the disease and provides an in vivo
chemosensitivity test for a particular regime. It is vital to
predict response to chemotherapy in order to tailor the
regime in a particular patient for an optimum response
and to avoid chemotoxicity in a non-responder. Various
markers like p-glycoprotein, p53, apoptotic markers and
toxicity etc. have been studied to assess and predict
response to NACT but the search for an ideal predictor is
still on[3,4].
Mismatch repair(MMR) genes first came into focus due to
their role in hereditary nonpolyposis colon cancer
(HNPCC) syndrome [5-10]. The dysfunction of these
genes has also been implicated in sporadic colorectal, gas-
tric, endometrial, prostatic, and hematological malignan-
cies. These genes repair the replicative errors of DNA and
are imperative for stability of the genome. MMR proteins
have been found to be involved in promoting cytotoxicity,
apoptosis and p53 phosphorylation. They have also been
found to be responsible for cell-cycle arrest following
exposure to exogenous DNA damaging agents, including
those agents that form DNA adducts not removed by
MMR, like thioguanine, cisplatin, carboplatin, doxoru-
bicin and etoposide [7-10].
With the loss of MMR function replicative errors are not
corrected, leading to instability of the genome. This can be
detected by polymorphisms in micro satellites (1–6 nucle-
otide repeat sequences scattered in whole of the genome)
[7-10]. This phenomenon, known as micro satellite insta-
bility (MSI) is a hallmark of MMR dysfunction in colorec-
tal and other malignancies. An alternative method for
detection of loss of MMR function is to test the expression
of protein products of the MMR genes i.e. MLH1, MSH2,
MSH6 and PMS2 by immunohistochemistry (IHC), as
mutations in these genes lead to reduced or absent expres-
sion of their gene products [7-10].
In colorectal cancers, MSI positivity imparts distinct clin-
icopathological features and response to chemotherapy
has been found to be favorable in MSI positive tumors.
Thus detection of MMR gene dysfunction is becoming an
essential tool in the management of these cancers. In
breast cancer, the role of MMR genes has been studied
increasingly in the past two decades and the detection rate
of MSI has been found to vary greatly(5 to 30 %) between
various studies [10-13]. There may be a correlation
between loss of MMR function in breast cancer and clini-
cal, histopathological, behavioral parameters of the
tumor and also its response to chemotherapy [10-14].
We studied 31 cases of locally advanced breast carcinoma
(LABC) for correlation between MMR dysfunction, clin-
icopathological parameters and response to chemother-
apy using immunohistochemistry for four MMR protein
products -MLH1, MSH2, MSH6 and PMS2, before and
after NACT.
Patients and methods
After approval by the Institutional Review Board and the
ethical committee of the hospital, 31 fine needle aspira-
tion cytology (FNAC) proven cases of LABC according to
AJCC (American Joint Committee on Cancer) classifica-
tion were included in the study. The tumor size and the
axillary lymph node status were assessed clinically and by
using ultrasonography. Core biopsy was performed for
immunohistochemical estimations of MMR proteins in
the specimen before initiating the chemotherapy. Blood
tests, chest radiographs, electrocardiography (ECG)
(echocardiography when ECG had a positive finding),
liver function tests, bone scan, ultrasonography (USG) of
the abdomen, renal function tests were routinely per-
formed in all the cases.
Three cycles of FAC regime (cyclophosphamide 500 mg/
m2, adriamycin 50 mg/m2, 5-fluorourail 500 mg/m2)
were given at three weekly intervals and the patients were
assessed both clinically and by ultrasound for response inInternational Seminars in Surgical Oncology 2007, 4:5 http://www.issoonline.com/content/4/1/5
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the form of reduction in breast tumor size and axillary
lymph node status. Patey's modified radical mastectomy
was performed three weeks after the last cycle and the
mastectomy specimen was examined for pathological
response, resected margins, axillary lymph node status
and IHC for MMR proteins.
The pathological tumor response was evaluated by size
measurement at the time of tumor resection macroscopi-
cally and by detecting tumor cell existence (or not) micro-
scopically. Clinical responders were defined as patients
with a complete (CR) or partial response (PR) [CR: com-
plete resolution of tumor, PR>50% regression in maxi-
mum diameter of initial tumor] after 3 cycles of NACT.
Non-responders were patients with a minimal response
(MR<50% regression in maximum diameter of initial
tumor), no change (NC) or local progression. Pathologi-
cal complete response (pCR) was defined as absence of
any gross or microscopic evidence of residual tumor in the
mastectomy specimen i.e. absence of residual invasive or
in situ disease following neoadjuvant chemotherapy. Its
assessment was done, irrespective of the clinical response
status. Clinical response was taken in to consideration for
statistical analysis as the pCR was observed in only 2
patients (n = 31).
Immunohistochemical method
The monoclonal mouse antibody, clone 124 (DAICD)
was used. Heating in water broth at 95 degree Celsius for
2 hours in 0.1 M-utrate buffer (6.0 pH) was done for anti-
gen-retrieval. The antibody localization was seen in the
cytoplasm of the cells and IHC staining was done by Avi-
din Biotin technique.
The staining was analyzed as per the intensity and the per-
centage of positive cells.
H-score was calculated for each of the four MMR proteins
and for this purpose the intensity of staining of tissue was
scored as 0–3 (absent, mild, moderate, intense) and per-
centage of positive staining cells were scored as 0–4. The
H-Score was calculated by multiplying these two scores
thus the minimum H-score being 0 and maximum 12.
Results
31 patients with locally advanced breast cancer were
included in this study, the mean age at presentation was
47.3 years,19(61.2%) were postmenopausal and 12
patients(38.7%) were premenopausal. The mean tumor
size was 6.7 cms and 22 out of 31 cases (70.9%) were N1
at presentation. Majority of tumors were infiltrating duc-
tal carcinomas (IDC) i.e. 25 out of 31. However two cases
of infiltrating lobular carcinomas mixed with IDC and
two cases of mucinous carcinoma including one of pure
lobular variety were also found (table 1). More than 50%
tumors were moderately differentiated while16.70% were
poorly differentiated and 30% were well differentiated
(table 2).
The objective clinical response rate observed in our study
was 54.83% with 17 patients (54.83%) being responders
including 2 patients with pathological complete
response(table 2). With the confidence limit of 99%
paired- t test was applied to the above table and response
to NACT in terms of down staging of the tumor size and
axillary lymph node status was found to be statistically
significant with a P-value of 0.000.The correlation
between these two parameters was studied using Spear-
man's rank correlation coefficient test with a confidence
limit of 95%.
Immunohistochemical analysis
Immunohistochemical results were analyzed using the H
score as described abov (tables 3, 4, 5, 6, 7, 8, 9, 10)
MMR expression in the core biopsy specimen of tumors 
before NACT
When MMR expression was rated as positive and negative,
MLH1 and MSH2 staining was negative in around 40% of
cases whereas MSH6 was negative in around 50% of cases,
for PMS2 the negative expression was found in only
29.03% patients(tables 3, 4, 5, 6).
The H-score for MLH1 was better than that for MSH2,
which showed poor staining in breast cancers. MSH6 was
the most frequently altered MMR gene, with negativity
rate of 48% while PMS2 was found to be the least altered
Table 1: 
Distribution of patients based on the histological types (n = 31)
Infiltrating duct carcinoma(IDC) Infiltrating lobular carcinoma mixed with IDC Mucinous carcinoma
25 (81.4%) 3 (9.3%) 3 (9.3%)
Distribution based on the differentiation (n = 31)
Well differentiated Moderately differentiated Poorly differentiated
9(30%) 17(53.3%) 5(16.7%)International Seminars in Surgical Oncology 2007, 4:5 http://www.issoonline.com/content/4/1/5
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MMR gene and it showed strong staining in most of the
tumors(tables 3, 4, 5, 6)
There was no significant correlation observed between
age, family history, T- size, lymph node status or histolog-
ical sub-type of tumor and expression of MMR in the core
cut biopsy. However, a significant  correlation was
observed between expression of MLH1 and MSH2 and
histological grade (p = 0.048 and 0.038 respectively),
tumors with negative or reduced H-scores of MLH1 and
MSH2 had lesser degree of differentiation. Out of the
twelve MSH2 negative cases in this study, four were poorly
differentiated and only one was well differentiated,
whereas, of the 19 MSH2 positive tumors 8 were well dif-
ferentiated. Histological grade is a known predictor of
poor outcome and this finding suggests that tumors with
negative expression of MMR are likely to be more aggres-
sive with a poor outcome in terms of survival.
The correlation of H-scores of all the four MMR gene
products with objective clinical response was studied sep-
arately and tested for significance. No significant correla-
tion was found between pre-NACT, H-scores and clinical
response for MLH1, MSH2, and MSH6 however a statisti-
cally significant negative correlation was observed
between PMS2 expression and clinical response (p =
.045). Cases with high post NACT expression of PMS2
were poor responders of chemotherapy (CAF regimen).
MMR expression after NACT
Immunohistochemistry was carried out after neoadjuvant
chemotherapy in the mastectomy specimen and H-scores
of all four MMR proteins were correlated with clinical
response. It was found that although, after neo-adjuvant
chemotherapy the mean H-scores of MLH1, MSH2 and
MSH6 and PMS2 were reduced as compared to pre-NACT
expression, the change in their expression was not statisti-
cally significant. However the mean H-score of PMS2
increased after chemotherapy, though the change was
again not statistically significant. There was no signifi-
cant correlation observed between clinical response
and H-scores of MLH1, MSH2, MSH6 and PMS2 after
neoadjuvant chemotherapy (Tables 6, 7, 8, 9, 10)
Discussion
DNA mismatch repair (MMR) pathway is an important
post-replicative repair process involved in the mainte-
nance of genomic stability [5-9]. The MMR genes repair
erroneous pairing of nucleotide bases, which can arise
through DNA replication, genetic recombination, deami-
nation of 5-methylcytosine to thymine and the action of
chemical mutagens. Upon binding to mismatch, the com-
plex protein undergoes a conformational change associ-
Table 4: MSH 2
Frequency Percent Valid percent Cumulative percent
0 12 38.71 38.71 38.71
2 8 25.81 25.81 64.52
4 3 9.67 9.67 74.19
6 7 22.58 22.58 96.77
9 1 3.22 3.22 100
12 0 0 0 100
Total 31 100 100
12 cases out of 31 (38.73%) had negative staining (score = 0) for 
MSH2.Out of the rest 19 cases the H-score of <2 was found in 8 cases 
thus the staining for MSH2 was less consistent than MLH1.
Table 2: 
Mean tumor size before and after NACT Mean N Std. Deviation Std. Error Mean
Pair 1 Pre NACT Tumor Size 6.82 31 2.64 .47
Post NACT Tumor size 4.37 31 2.6171 .4701
Mean N Stage before and after NACT
---------- Mean N Std. Deviation Std. Error Mean
Pair 2 Pre NACT N stage 1.16 31 .52 .13
Post NACT N stage .81 31 .65 .12
Table 3: DISTRIBUTION ACCORDING TO H-SCORE MLH1
Frequency Percent Valid percent Cumulative percent
0 13 41.93 41.93 41.93
2 2 6.45 6.45 48.38
4 2 6.45 6.45 54.83
6 9 29.03 29.03 83.86
9 5 16.7 16.7 100
12 0 0 0 100
Total 31 100 100
13 cases out of 31 (41.93%) had negative staining (score = 0) for 
MLH1.Out of the rest 18 cases only 2 had a H-score less than 2 
signifying that staining, when present is remarkable.International Seminars in Surgical Oncology 2007, 4:5 http://www.issoonline.com/content/4/1/5
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ated with exchange of bound ADP from ATP resulting in
the formation of a clamp that can translocate along the
DNA. Thus erroneous pairing is recognized, excised and
replaced with the correct one[7,8].
The hallmark of MMR dysfunction is micro satellite insta-
bility (MSI).Micro satellites are repeated regions of one to
six nucleotide units that occur primarily in non-coding
regions and the number of micro satellite repeat units
located at a given locus is genetically determined. Micro
satellite instability can occur during replication of repeti-
tive sequences when two strands of DNA-the strand that is
being copied and the new one being synthesized, slip rel-
ative to one another resulting in small loops of unpaired
DNA.
Normally, after replication, the mismatch repair system
which is carried out by products of four mismatch repair
genes (MMR) i.e. hMSH2, hMLH1, hPMS2 and hMSH6
and a few others, would recognize mismatched base pairs
and replace them with correct nucleotides. The efficiency
of heteroduplex repair is much reduced in cells with muta-
tions in MMR genes [7-10].
These genes have been studied most extensively in colon
cancers and have been found to impart certain clinical and
pathological characteristics to the tumor [5-9]. In breast
cancers also, MMR dysfunction has been studied quite
extensively and in sporadic breast cancers the reported fre-
quency of MSI has varied widely. Yee et al. [18] used seven
micro satellites against twenty breast neoplasms and
found instability in four of them (20%). At extreme odds
with other reports Patel et al [19] detected MSI in 11 of 13
(85%) tumors using 9 microsattelites. The greatest prob-
lem in comparing the results of different series is the fact
that each series generally used a different set of micro sat-
ellite markers thus making true comparison impossible
[10-17].
In contrast to HNPCC syndrome there is less concordance
between MSI and MMR gene dysfunctions in breast can-
cer. This absence of correlation between MMR function
loss and MSI suggest oncogenetic mechanism of progres-
sion in primary breast cancer different from that in
HNPCC. This lack of correlation between MMR dysfunc-
tion and MSI could be due to involvement of MMR genes
not leading to MSI formation like MLH6 or PMS2.Thus in
breast cancers immunohistochemistry for MMR protein
products would appear to be more logical for detection of
loss of MMR function [9-16].
The studies correlating the clinical pathological parame-
ters of breast cancer with MMR dysfunction suggest an
association between MSI and poor clinico- pathological
features namely: larger tumor size, positive nodal status,
advanced stage, negative expression of hormone receptors
and decreased disease free and overall survival [9,12-14].
In the present study, no significant correlation was found
between any of the MMR gene-products with age, family
history, T-size, N-stage and histotype. There was a strong
correlation observed between expression of MLH1 and
MSH2 with the histological grading of tumor, which is a
known predictor of poor outcome in breast cancer. The
lack of correlation observed in the present study could be
explained partly on the basis of selection criteria for this
study, which included only locally advanced breast can-
cers.
MMR protein MutSα (a heterodimer of MSH2 and MSH6)
recognizes and binds to sites of DNA damage, such as O6-
methylguanine and 1,2-cisplatin intrastrand cross links,
and is proposed to lead to recruitment of MutLα (a het-
erodimer of MLH1 and PMS2 O6-methylguanine) into the
complex. This has been suggested to lead to either futile
rounds of DNA repair or replication stalling and activa-
tion of an apoptotic pathway [14-17].
Table 6: PMS2
Frequency Percent Valid percent Cumulative percent
0 9 29.03 29.03 29.03
2 5 16.12 16.12 45.15
3 2 6.45 6.45 51.60
4 1 3.22 3.22 54.82
6 9 29.03 29.03 83.85
9 2 6.45 6.45 90.3
12 3 9.67 9.67 100
Total 31 100 100
Amongst all MMR products the H-score was highest forPMS2. Also 
negativity rate was only 29.03%
Table 5: MSH6
Frequency Percent Valid percent Cumulative percent
0 15 48.39 48.39 48.39
2 5 16.12 16.12 64.57
3 2 6.45 6.45 70.97
4 5 16.12 16.12 87.08
6 1 3.22 3.22 90.3
9 1 3.22 3.22 93.52
12 2 6.45 6.45 100
Total 31 100 100
15 cases had negative expression for MSH6 and the rest 16 stained 
variably for MSH6 with some tumors showing H-score of 12.International Seminars in Surgical Oncology 2007, 4:5 http://www.issoonline.com/content/4/1/5
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For topoisomerase II inhibitors (such as doxorubicin),
MMR proteins may serve as a detector of the cleavable
complex produced by the binding of the drug to topoi-
somerase II. Alternatively, doxorubicin is known to partic-
ipate in redox cycling reactions that produce DNA damage
including cross-links that may be recognized by MMR.
Furthermore MMR activity can be restored to extracts of
defective cell lines by complementation with complexes
of hMSH2 and GTB, hMLH1 or PMS2 or by introducing a
human chromosome with wild type copy of MLH1.How-
ever in most of cancers in a clinical scenario MSI and loss
of MMR function is associated with a favorable response
to chemotherapy. In breast cancers there have been few
studies to delineate MMR dysfunction and response to
chemotherapy [18-20].
The role of hMLH1 as predictor of response to therapy by
correlation with disease-free survival was assessed in a
study with patients receiving regimens containing doxoru-
bicin or cisplatin, drugs exhibiting resistance in vitro asso-
ciated with loss of MLH1 expression [12]. Further, the
expression of MLH1 in tumors from women with clini-
cally node-positive breast cancer was compared before
and after primary (neoadjuvant) chemotherapy: Immu-
nohistochemistry scores of MLH1 were made on 36 tru-
cut prechemotherapy biopsies and 29 paired post chemo-
therapy tumor samples. MLH1 expression before chemo-
therapy did not predict disease-free survival or tumor
response to chemotherapy. Low MLH1 expression after
chemotherapy, however was an independent predictor of
poor disease-free survival [12-21].
In another study Immunohistochemical studies were per-
formed on 71 histological specimens of breast cancer
taken from the patients treated with surgery and subse-
quent cyclophosphamide, methotrexate, and 5-fluorour-
acil (CMF) or cyclophosphamide, Adriamycin, and 5-
fluorouracil (CAF) chemotherapy for stage II or III pri-
mary breast cancer[22]. Positive expression of hMLH1-IS
and hMSH2-IS were 57.7% and 60.6%, respectively, and
complete losses of hMLH1 and hMSH2 were observed in
4.2% of patients. Amongst the patients of advanced can-
cer with lymph node metastasis, those having a low
hMLH1-IS had a significantly higher failure rate with the
CMF regimen than those having a high hMLH1-IS (p =
0.03). No significant difference was noted in chemothera-
peutic response according to hMLH1 and hMSH2 expres-
sion in the group receiving the CAF regimen[22].
In the present study no significant correlation was found
between pre or post chemotherapy MLH1 or MSH2
expression or H-score and response. There was however a
significant correlation between clinical response and H-
score of PMS2 before neo-adjuvant chemotherapy using
CAF regime (P = 0.045) while no significant correlation
was found between post chemotherapy MLH1 expression
and response.
Previous studies have linked MMR proteins to the activa-
tion of apoptosis through p53-dependent and p53-inde-
pendent mechanisms. MMR-deficient cells exhibit
variable defects in the induction of p53 and its related
p73, which are activators of apoptosis. An interaction
between PMS2, an MMR protein, and p73 has been
Table 8: MSH2
SCORE Percentage of cells staining Frequency Percent Valid percent Cumulative percent
0 0% 12 38.70 38.70 38.70
1 <5% 0 0 0 38.70
2 5–20% 11 35.48 35.48 74.18
3 20–80% 8 25.80 25.80 100
4 80–100% 0 0 0 100
Like the results of H-score for MSH2, score based on percentage of positively staining cells for MSH2 was also low for most of the tumors. 23 cases 
out of 31 had a score of less than 2.
Table 7: MLH1
SCORE Percentage of cells staining Frequency Percent Valid percent Cumulative percent
0 0% 13 41.93 41.93 41.93
1 <5% 0 0 0 41.93
2 5–20% 4 12.90 12.90 54.83
3 20–80% 14 45.16 45.16 100
4 80–100% 0 0 0
Of the 18 cases staining positive 14 had staining in more than 80 % of cells. This result correlated well with the results of H-scoring.International Seminars in Surgical Oncology 2007, 4:5 http://www.issoonline.com/content/4/1/5
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described which results in stabilization of p73 and redis-
tribution of PMS2 to the nuclear compartment. Exposure
to cisplatin enhances the association between PMS2 and
p73. Moreover, stimulation of the p73 pro-apoptotic
function by cisplatin requires PMS2. These results suggest
that PMS2 contributes to genome integrity not only
through DNA repair but also by enhancing DNA damage-
induced apoptosis [22-28].
No studies evaluating the predictive value of PMS2 in
breast cancer chemotherapy has been done yet. In the
present study an inverse relationship was found between
H-score of PMS2 and response to CAF regimen chemo-
therapy. Tumors with low scores responded better to
chemotherapy as seen in other tumors like colonic malig-
nancies.
In the present study 54.83% of patients had a significant
objective clinical response to NACT (in terms of reduction
in tumor size and down staging of the axillary lymph
node status). A significant negative correlation was
observed between PMS2 H-score after neo-adjuvant
chemotherapy and clinical response. The patients with
high H-scores expression responded poorly to NACT. No
studies evaluating the predictive value of PMS2 in breast
cancer chemotherapy have been done yet and in the
present study an inverse relationship was observed
between H-score of PMS2 and response to CAF regimen
chemotherapy.
There was no significant correlation observed between
expression of MMR proteins and age of the patient, family
history, tumor size or histological type of the tumor, while
a strong negative correlation was observed between
expression of MLH1 and MSH2 and histological grading
of the tumor, which is a reliable predictors of outcome in
the treatment of breast cancer. The study also highlights
the possible role of MMR expression in predicting aggres-
sive tumor behavior in view of the statistically significant
negative correlation between MLH1 and MSH2 expres-
sion and histological grade. The tumors with low expres-
sion of MLH1 and MSH2 are expected to have a better
outcome.
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Table 10: PMS2
SCORE Percentage of cells staining Frequency Percent Valid percent Cumulative percent
0 0% 9 29.03 29.03 29.03
1 <5% 0 0 0 29.03
2 5–20% 6 19.35 19.35 48.38
3 20–80% 14 45.16 45.16 93.81
4 80–100% 2 6.45 6.45 100
Only 9 cases had a score of 0 for PMS2 and rest all (i.e.22 out of 31) had a score of more than 2.
Table 9: MSH6
SCORE Percentage of cells staining Frequency Percent Valid percent Cumulative percent
0 0% 15 48.38 48.38 48.38
1< 5 % 0 0 00
2 5–20% 5 16.12 16.12 64.5
3 20–80% 8 25.80 25.80 90.3
4 80–100% 3 9.67 9.67 100
The results of score based on percentage of positively staining cells were similar to that of H-score with both showing variable staining in positively 
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